Available Options for CAR T-Cell Therapy in Patients With RRMM
Dr Dhakal outlines the FDA-approved CAR T-cell therapy products for patients with multiple myeloma who have undergone at least four prior lines of treatment, emphasizing a focus on individualized decision-making when selecting patients for CAR-T.
EP: 1.Patient Case Presentation: A 47-Year-Old Man With Multiple Myeloma
EP: 2.Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
EP: 3.Talquetamab in RRMM: Results From MonumenTAL-1
EP: 4.Teclistamab Plus Talquetamab in RRMM: Data from the RedirecTT-1 Study
EP: 5.Teclistamab plus Nirogacestat in RRMM: The MAJESTEC-2 Study
EP: 6.Bispecific-Based Combinations Under Evaluation for Patients with RRMM
EP: 7.Toxicity Management in Patients With RRMM Receiving Bispecific Antibodies
EP: 8.Treatment Approaches for Frail Patients With RRMM
EP: 9.Patient Case Presentation: A 62-Year-Old Woman With High-Risk Multiple Myeloma
Now Viewing
EP: 10.Available Options for CAR T-Cell Therapy in Patients With RRMM
EP: 11.Ciltacabtagene Autoleucel in Patients With MM: Efficacy and Safety Data From CARTITUDE-1
EP: 12.Clinical Pearls for Community Physicians Treating Patients With RRMM With CAR T-Cell Therapy
EP: 13.Toxicity Management in Patients With R/R MM Receiving CAR T-Cell Therapy
EP: 14.Exploring Novel Treatment Options in Patients With RRMM
EP: 15.Analyzing a Patient Case and Assessing Treatment After Relapse in Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
